trial

Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia

NCTId NCT00235352
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 105 (actual)
Sponsored by North Suffolk Mental Health Association
Primary completion 2005-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
105 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2002-02
Primary completion
2005-04
Eligibility
18 Years · 65 Years

Interventions & indications

Drugs
CX516 (Ampakine)

Sponsors

North Suffolk Mental Health AssociationLead Sponsor
RespireRxCollaborator

Investigators

1
Donald C. Goff, MDPrincipal Investigator

Sites

1 total
Boston, United States

Linked catalysts

1
Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With — primary completion2005-04

Facts & assertions

4 sourced
Enrollment
105
Phase
PHASE2,PHASE3
Primary Completion Date
2005-04
Status
COMPLETED
relationships
The graph out of here
drug
CX516 (Ampakine)
drug
lead_sponsor
North Suffolk Mental Health Association
company
collaborator
RespireRx
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Donald C. Goff, MD
person